Details for New Drug Application (NDA): 022502
✉ Email this page to a colleague
NDA 022502 describes DIFFERIN, which is a drug marketed by Galderma Labs Lp and is included in five NDAs. It is available from four suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DIFFERIN profile page.
The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the adapalene profile page.
The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the adapalene profile page.
Summary for 022502
| Tradename: | DIFFERIN |
| Applicant: | Galderma Labs Lp |
| Ingredient: | adapalene |
| Patents: | 3 |
Medical Subject Heading (MeSH) Categories for 022502
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | LOTION;TOPICAL | Strength | 0.1% | ||||
| Approval Date: | Mar 17, 2010 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | May 31, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF ACNE | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 15, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF ACNE | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Sep 15, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF ACNE | ||||||||
Complete Access Available with Subscription
